PIK3CA Mutations in Resected Small Cell Lung Cancer

Han, Na; Cheng, Qiaoyuan; Chen, Bin; Cai, Jianhui; Wang, Xiao-Jia; Lou, Chenghua; Qin, Jing; Ye, Wei-Wu; Lei, Lei; Lu, Hongyang

doi:10.17219/acem/25928

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis did not reveal any mutations in exons 9 and 20 of the PIK3CA gene in the tumor tissue of patients with SCLC. 53 In the current study, one patient presented the PIK3CA mutation. The percentage of PIK3CA mutations is similar to PTEN: ~5%.…”

Section: ° °mentioning

confidence: 66%

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

Mao

Cheng

et al. 2014

JCO

Self Cite

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) is an aggressive and deadly neuroendocrine tumor derived from bronchial epithelial cells. Although it results in a 95% mortality rate, the development of targeted therapies for SCLCs has lagged behind. The aim of this study is to better research mutation characteristics of SCLC and identify potential biomarkers for target therapy. Methods: We utilized high-resolution melting analysis to identify the mutations in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), phosphatase and tensin homolog (PTEN), and phosphatidylinositol-3-kinase catalytic (PIK3CA) from the blood. A cohort of 99 SCLC patients including 44 limited-stage disease patients and 55 extensive-stage disease patients were prospectively collected. Results: EGFR 18 (G719X) mutation was found in 5 patients, EGFR 19 (del) mutation in 2, EGFR 20 (T790M) in 3, EGFR 21 (L858R) in 2, KRAS 2 (G13D) in 5, BRAF 15 (V600E) in 1, PIK3CA 9 (E542K) in 1, and no mutations in PTEN 5 (R130G), PTEN 6 (R173C), PTEN 8 (T319fs*1), and PIK3CA 20 (H1047R) were identified. Among these patients, two harbored EGFR double mutation, one patient with EGFR double mutation and KRAS 2 (G13D) mutation. Conclusion: The mutation form of EGFR may differ from lung adenocarcinoma, and mutations of KRAS, BRAF, and PIK3CA were rare in SCLC. These results aided us in comprehensively analyzing genetic features and laid the foundation for exploring the possibility of target therapy.

show abstract

Section: ° °mentioning

confidence: 66%

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

Mao

Cheng

et al. 2014

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, it can activate the downstream Akt, causing independent cell proliferation and enhancing the ability of cells to metastasize. 50 , 51 A series of PIKK3CA mutations have been reported in various cancer lines, including SCLC (3.4–4.3%), colorectal cancer (30–40%), ovarian cancer, thyroid, 52 , 53 cancer, 54 gastric cancer, and breast cancer (7–40%). 55 This gene has also been targeted in previous studies of SCLC.…”

Section: Discussionmentioning

confidence: 99%

Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer

Jiao

Zhang

Wang

et al. 2022

CMAR

View full text Add to dashboard Cite

Introduction Small cell lung cancer (SCLC), an aggressive subtype of lung cancer characterized by the development of neuroendocrine tumors, is prone to distant metastasis, resistant to platinum-based drugs and has a poor prognosis. The development of next-generation sequencing technology (NGS) has led to the identification of many genetic alterations in SCLC. Few druggable targeted molecules can be used in clinical practice. Currently, NGS is widely employed in routine clinical practice of non-small cell lung cancer to assist in therapeutic options and prognosis evaluation. This study aims to investigate genes involved in small cell lung cancer (SCLC), their occurrence and their significance in clinical events. Methods Tumor tissue specimens from 18 Chinese SCLC patients were collected through a 520 cancer‐related genes panel for next-generation sequencing. First, the association between sequence results and clinical outcomes was examined. Subsequently, data on clinical pathology and sequencing results were analyzed. Results The Kaplan–Meier curve displayed a significant reduction in PFS for SCLC patients with LRP1B or MAP3K13 mutations. Overall survival (OS) of SCLC patients with MSH6 mutation was significantly higher than those with SPEN mutation. Conclusion Next-generation sequencing demonstrates that the genetic landscape of SCLC. Mutation status of LRP1B, MAP3K13, MSH6 and SPEN has prognostic significance, which might be potential therapeutic targets. We found possible genes and related signaling pathways that affect metastasis. These results can improve our understanding of the mutation characteristics of SCLC and identify potential biomarkers to guide targeted therapies.

show abstract

miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition

Fang

Zhang

2019

Experimental Cell Research

View full text Add to dashboard Cite

PIK3CA Mutations in Resected Small Cell Lung Cancer

Cited by 4 publications

References 19 publications

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer

miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition

Contact Info

Product

Resources

About